Greenland Mines Ltd GRML
Greenland Mines Ltd (Nasdaq: GRML) is a CNS/neurology/psychiatry life-science company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KLTO-202 (alpha-Klotho gene therapy) | ALS / neurodegenerative disease | gene therapy | — |
| Off-patent generic oncology drug portfolio (German market authorizations) | Cancer | small molecule | — |
| Biosimilar biologics (in-licensed from RLS) | Cancer | antibody | — |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.